Vaxxinity, Inc. (VAXX)

OTC Markets OTCPK Currently unchanged in today's trading session

1 member of Congress has disclosed 6 trades in Vaxxinity, Inc. (VAXX) via STOCK Act filings. The most recent disclosure was a sale by Rick Scott on 20 December 2023. Aggregate disclosed activity totals roughly $48K in sales (midpoint estimates from bracketed disclosure amounts).

Vaxxinity, Inc. is currently trading at $0.00, positioned at 0% of its 52-week range ($0.00 – $0.20).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$0.00
24h Change
0.00 (0.00%)
52 Week Range
$0.00$0.20
View on NASDAQ

Vaxxinity, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for VAXX

Select to highlight on chart
3 transactions
Compliance: 50%
Rick Scott20 Dec 202319 Jan 2024SaleStock$1,001 - $15,000N/A
Rick Scott20 Dec 202319 Jan 2024SaleStock$1,001 - $15,000N/A
Rick Scott20 Dec 202319 Jan 2024SaleStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$12.68K

Volume

510

Beta

3.78

P/E Ratio

Fundamentals

EPS

$-0.45

Div. Yield

Open

$0.00

Day Range

$0.00 — $0.00

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
OTC · USD
Country
US
CEO
Mei Mei Hu
IPO Date
2021-11-11

Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and...

Earnings

Next Report

Q2 2026

28 Aug

EPS Est.

$-0.12

Rev. Est.

Days Until

0

Recent Quarters

Q1 202627 May
EPS
Q1 20255 Jun
EPS
Q4 202427 Mar
EPS
Q3 202418 Nov
EPS
Q2 202430 Sept
EPS
Q1 202414 May
EPS$-0.15
Miss 50.0%
Q4 202327 Mar
EPS$-0.09
Beat 30.8%
Q3 20238 Nov
EPS$-0.10
Beat 28.6%
Q2 20239 Aug
EPS$-0.11
Beat 31.3%
Q1 20239 May
EPS$-0.15
Beat 6.3%
Q4 202227 Mar
EPS$-0.16
Beat 0.0%
Q3 202210 Nov
EPS$-0.15
Beat 6.3%
Q2 202211 Aug
EPS$-0.14
Beat 63.2%
Q1 20229 May
EPS$-0.15
Beat 55.9%
Q4 202124 Mar
EPS$-0.48
Miss 37.1%
Q3 202123 Dec
EPS$-0.24
Miss 84.6%
Q3 202112 Nov
EPS$-0.22
Q4 202031 Mar
EPS$-0.26
Q3 202031 Dec
EPS$-0.10
Q2 202030 Sept
EPS$-0.13
Q1 202030 Jun
EPS$-0.06
Q4 201931 Mar
EPS$-0.11

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about VAXX

Which members of Congress have traded VAXX?
1 member of Congress has disclosed 6 trade in Vaxxinity, Inc. (VAXX) under the STOCK Act: Rick Scott.
When was VAXX most recently disclosed by Congress?
The most recent VAXX disclosure was a sale by Rick Scott on 20 December 2023.
What is the total disclosed congressional trading volume for VAXX?
Members of Congress have disclosed approximately $48K in VAXX sales (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in VAXX?
This VAXX page updates as soon as new STOCK Act disclosures are filed for Vaxxinity, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.